Acute changes of coagulation and fibrinolysis parameters after experimental thromboembolic stroke and thrombolytic therapy.
Thrombolysis is the only effective pharmaceutical therapy in acute ischemic stroke in humans but has a high risk of intracerebral hemorrhage. We aimed to establish an animal model to study changes of coagulation and fibrinolytic parameters during thromboembolic ischemic stroke and thrombolysis with recombinant tissue plasminogen activator (rt-PA). We used a thromboembolic stroke model in the rat. Animals were treated with rt-PA thrombolysis (n=10) and compared with untreated (n=10), sham operated (n=10) and control animals (n=20). Coagulation parameters (APTT, PT, TT, fibrinogen, AT III, TAT) and fibrinolytic parameters (t-PA antigen concentration, t-PA activity, PAI-1 concentration, PAI activity, plasminogen, antiplasmin) were measured at two time points (2.5 and 5h after stroke induction) with a battery of commercially available test kits. We observed an (1) initiation of coagulation and inhibition of fibrinolysis by the operation procedure itself, (2) simultaneous activation of fibrinolysis and its inhibitors after stroke induction and (3) potent initiation of fibrinolysis and consumption of fibrinolysis inhibitors after rt-PA therapy of stroke. We established a model system to monitor coagulation and fibrinolysis during thrombolytic therapy of stroke in the rat. This model may be used to study the influence of these parameters on hemorrhagic stroke transformation and outcome in experimental stroke in future.
Stehling
Florian
F
Children's Hospital, University of Duisburg-Essen, Germany. Florian.Stehling@uk-essen.de <Florian.Stehling@uk-essen.de>
Weber
Ralph
R
Ozcelik
Arzu
A
Bröcker
Martina
M
Volbracht
Lothar
L
Diener
Hans-Christoph
HC
Busch
Elmar
E
D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects*; D004195:Disease Models, Animal; D005342:Fibrinolysis / Q000187:drug effects*; D008297:Male; D010958:Plasminogen / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology; D013923:Thromboembolism / Q000150:complications; D015912:Thrombolytic Therapy / Q000379:methods*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D010958:Plasminogen; D010959:Tissue Plasminogen Activator